Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
24.64
-0.33 (-1.32%)
Aug 15, 2025, 10:47 AM - Market open
Janux Therapeutics Employees
Janux Therapeutics had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.
Employees
81
Change (1Y)
17
Growth (1Y)
26.56%
Revenue / Employee
$5,420
Profits / Employee
-$1,304,210
Market Cap
1.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JANX News
- 7 days ago - Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 9 days ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
- 15 days ago - Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
- 21 days ago - Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
- 4 weeks ago - Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - Business Wire
- 3 months ago - Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Business Wire
- 3 months ago - Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire